Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Ascending Doses of HSK31858 in Healthy Volunteers
NCT05023525Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Non-cystic fibrosis bronchiectasis (NCFB) comparing HSK31858 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Oct 2021; status: completed.
02
Drugs
HSK31858
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT05023525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023525.